Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490000 | 0.88 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL14492938 | 0.87 | OPRD1 (0.58) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5488298 | 0.87 | OPRD1 (0.60) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879336 | 0.76 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6325251 | 0.76 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| SCHEMBL14492935 | 0.75 | OPRD1 (0.77) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5488301 | 0.74 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6327827 | 0.73 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5492915 | 0.73 | OPRD1 (0.76) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5879367 | 0.72 | OPRD1 (0.43) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226933-B2 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1395555-B1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERATIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040235897-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | BROWN WILLIAM (CA) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235897-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR1D, HTR2C, HTR3C | OPRD1 6/4885OPRM1 5/4885OPRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.